Table 5.
Results of recent scalp-cooling studies.
| References | N | Study design | Scalp-cooling method | Cancer type | Chemotherapy agents | Observation period | Hair preservation | % of hair preservation (controls) |
|---|---|---|---|---|---|---|---|---|
| Nangia et al. (6) | 182 | Randomized control | Paxman cooling system | Early-stage breast cancer | Taxane and/or anthracycline based | During chemotherapy | CTCAE grade ≦ 1 assessed by independent clinicians | 51% (0%) |
| Smetanay et al. (15) | 79 | Randomized control | Dignicap cooling system | Breast cancer (stages 1–3) | Taxane and/or anthracycline based | 6 months after chemotherapy | Dean grade ≤ 2 assessed by patients | 39% (0%) |
| Rugo et al. (7) | 122 | Non-randomized controlled | Dignicap cooling system | Early-stage breast cancer | Taxane based | 4 weeks after completion of chemotherapy | Dean grade ≤ 2 assessed by patients | 66% (0%) |
| Betticher et al. (16) | 238 | Non-randomized controlled | Paxman cooling system/Cold Cap | Breast, lung, prostate cancer, etc. | Docetaxel | During chemotherapy | WHO grade ≤ 2 assessed by physician, and no wig required | 82% (36%) |
| Chan et al. (17) | 60 | No control | Dignicap cooling system | Breast cancer (stages 1–3) | Taxane and/or anthracycline based | 2–4 weeks after completion of chemotherapy | Dean grade ≤ 2 assessed by patients | 33% |
| Vasconcelos et al. (18) | 131 | No control | Paxman cooling system | Breast cancer (stages 1–3) | Taxane and/or anthracycline based | During chemotherapy | Visual evaluation ≤ 50% hair loss assessed by nurse and no wig required | 71% |
| Rice et al. (19) | 103 | Registry | Penguin Cold Caps | Early or advanced stage breast cancer | Taxane and/or anthracycline based | 4 weeks after completion of chemotherapy | VAS ≤ 50% hair loss assessed by patients | 61% |
| Van den Hurk et al. (14) | 1411 | Registry | Paxman cooling system | Breast, female genital, gastrointestinal/colorectal, lung, prostate cancer, etc. | Various | During chemotherapy | No wig required | 50% |
| Present study | 48 | Non-randomized controlled | Paxman cooling system | Early-stage breast cancer | Taxane or anthracycline based | 3 months after chemotherapy | CTCAE grade ≤ 1 assessed by two independent clinicians | 27% (0%) |
VAS, Visual analog scale; WHO, World Health Organization.